NOPE37: Angiogenic Factors for Managing Term Preeclampsia

NANot yet recruitingINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

April 30, 2028

Conditions
Preeclampsia
Interventions
OTHER

Intervention arm: expectant management if sFlt-1/PlGF<38

If the angiogenic factors are normal (sFlt-1/PlGF \<38), expectant management will be followed until 39 weeks, instead of delivery at ≥37 weeks of gestation as in standard care for preeclampsia without severe features.

OTHER

Standard care: elective delivery at 37 weeks of gestation

In the control arm, standard care for preeclampsia without severe features will be followed: elective delivery at ≥37 weeks of gestation.

Trial Locations (1)

Unknown

Vall d'Hebron Hospital Campus, Barcelona

All Listed Sponsors
collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER

NCT07193680 - NOPE37: Angiogenic Factors for Managing Term Preeclampsia | Biotech Hunter | Biotech Hunter